MX2015006444A - Tratamiento de la disritmia talamocortical. - Google Patents

Tratamiento de la disritmia talamocortical.

Info

Publication number
MX2015006444A
MX2015006444A MX2015006444A MX2015006444A MX2015006444A MX 2015006444 A MX2015006444 A MX 2015006444A MX 2015006444 A MX2015006444 A MX 2015006444A MX 2015006444 A MX2015006444 A MX 2015006444A MX 2015006444 A MX2015006444 A MX 2015006444A
Authority
MX
Mexico
Prior art keywords
tlves
tms
therapy
patient
treatment
Prior art date
Application number
MX2015006444A
Other languages
English (en)
Spanish (es)
Inventor
Steven Richard Devore Best
Original Assignee
Steven Richard Devore Best
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven Richard Devore Best filed Critical Steven Richard Devore Best
Publication of MX2015006444A publication Critical patent/MX2015006444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0055—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/048—Anaesthetics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/042—Force radial
    • F04C2270/0421—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Developmental Disabilities (AREA)
  • Social Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Treatment Devices (AREA)
MX2015006444A 2012-11-25 2013-11-21 Tratamiento de la disritmia talamocortical. MX2015006444A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729625P 2012-11-25 2012-11-25
US13/826,250 US8974365B2 (en) 2012-11-25 2013-03-14 Treatment of thalamocortical dysrhythmia
PCT/US2013/071275 WO2014081948A1 (en) 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia

Publications (1)

Publication Number Publication Date
MX2015006444A true MX2015006444A (es) 2015-10-29

Family

ID=50773848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006444A MX2015006444A (es) 2012-11-25 2013-11-21 Tratamiento de la disritmia talamocortical.

Country Status (10)

Country Link
US (5) US8974365B2 (enExample)
EP (2) EP2922591B1 (enExample)
JP (5) JP2016501865A (enExample)
KR (5) KR20150091323A (enExample)
CN (1) CN104981265A (enExample)
CA (1) CA2896568C (enExample)
ES (1) ES2882619T3 (enExample)
IL (2) IL273912B2 (enExample)
MX (1) MX2015006444A (enExample)
WO (1) WO2014081948A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155114B2 (en) * 2014-06-03 2018-12-18 Dirk De Ridder Systems and methods of treating a neurological disorder in a patient
US10118038B2 (en) * 2015-03-24 2018-11-06 Dirk De Ridder Methods of neuromodulation
US10201708B2 (en) 2014-10-29 2019-02-12 Dirk De Ridder Method of treating a neurological disorder using network stimulation
WO2017141257A1 (en) * 2016-02-21 2017-08-24 Tech Innosphere Engineering Ltd. Noninvasive electric brain stimulation system
US10596378B2 (en) * 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US20200222656A1 (en) 2016-10-18 2020-07-16 Joseph Rustick Method for treatment of depression using synaptic pathway training
US9950189B1 (en) * 2016-10-20 2018-04-24 Neuro-Laser Foundation Inc. Treatment methodologies using light therapy
US10905897B2 (en) * 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
AU2018371628B2 (en) * 2017-11-22 2021-08-12 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
KR102099200B1 (ko) * 2017-12-18 2020-04-09 서울대학교산학협력단 뇌 자극 장치
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
CN109481845B (zh) * 2018-12-28 2022-04-01 深圳先进技术研究院 一种作用于不同脑区的经颅磁刺激的方法和相关装置
CN110064117B (zh) * 2019-03-27 2021-06-01 佛山职业技术学院 一种基于呐喊声音的心理宣泄交互方法及装置
JP7413357B2 (ja) 2019-03-28 2024-01-15 住友建機株式会社 ショベル及び施工システム
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US12059565B1 (en) * 2019-12-19 2024-08-13 Washington University Methods and systems for modulating unconsciousness or anesthesia in a subject
CN113041501A (zh) * 2021-03-22 2021-06-29 东南大学 联合磁刺激系统靶向视觉皮层快速抗抑郁的方法
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression
AU2022281481A1 (en) * 2021-05-27 2023-12-14 Mcgrx Corp. Adjunctive d-cycloserine augmentation of transcranial magnetic stimulation (tms) therapy for major depressive disorder
ES2994763B2 (es) * 2023-07-25 2025-11-03 Nauta Technomedical Res S L Sistema de neuroestimulacion magnetica hiperbarica con ajuste parametrico semi automatico personalizable
WO2026076413A1 (en) * 2024-10-04 2026-04-09 Ampa Inc. Methods for modulating neuroplasticity

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US6132361A (en) * 1994-11-28 2000-10-17 Neotonus, Inc. Transcranial brain stimulation
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US20110307029A1 (en) * 2008-08-06 2011-12-15 Cerephex Corporation Brain stimulation methods for treating central sensitivity
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US8052591B2 (en) * 2006-05-05 2011-11-08 The Board Of Trustees Of The Leland Stanford Junior University Trajectory-based deep-brain stereotactic transcranial magnetic stimulation
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006057734A1 (en) * 2004-10-21 2006-06-01 Advanced Neuromodulation Systems, Inc. New stimulation design for neuromodulation
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CN101686945A (zh) * 2004-11-23 2010-03-31 埃德莫斯药品有限公司 包含持续释放的包衣或基质和nmda受体拮抗剂的组合物，以及向受治疗者施用该nmda受体拮抗剂的方法
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2007103475A2 (en) * 2006-03-07 2007-09-13 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US7949403B2 (en) * 2007-02-27 2011-05-24 Accelerated Care Plus Corp. Electrical stimulation device and method for the treatment of neurological disorders
WO2009137843A2 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010009141A1 (en) * 2008-07-14 2010-01-21 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and devices for modulating cellular activity using ultrasound
US8801589B2 (en) * 2008-08-04 2014-08-12 The Trustees Of Columbia University In The City Of New York Methods, apparatus, and systems for magnetic stimulation
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
CA2754189A1 (en) 2009-03-02 2010-09-10 Yeda Research And Development Co. Ltd. Magnetic configuration and timing scheme for transcranial magnetic stimulation
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CN102648200A (zh) * 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
CA2784119A1 (en) 2009-12-15 2011-06-23 Neurop, Inc. Compounds for the treatment of neurologic disorders
WO2011123548A2 (en) * 2010-04-02 2011-10-06 Neostim, Inc Neuromodulation of deep-brain targets by transcranial magnetic stimulation enhanced by transcranial direct current stimulation
US20140058189A1 (en) * 2012-02-20 2014-02-27 William F. Stubbeman Systems and methods using brain stimulation for treating disorders

Also Published As

Publication number Publication date
CA2896568C (en) 2025-06-17
EP2922591B1 (en) 2021-05-12
US20240207630A1 (en) 2024-06-27
JP2025029043A (ja) 2025-03-05
US8974365B2 (en) 2015-03-10
US10716950B2 (en) 2020-07-21
WO2014081948A1 (en) 2014-05-30
KR20250046361A (ko) 2025-04-02
IL238979A0 (en) 2015-07-30
KR20200117062A (ko) 2020-10-13
IL273912B1 (en) 2024-07-01
KR20230141875A (ko) 2023-10-10
JP2019065021A (ja) 2019-04-25
JP2022188221A (ja) 2022-12-20
KR20150091323A (ko) 2015-08-10
EP2922591A4 (en) 2016-08-10
EP2922591A1 (en) 2015-09-30
JP2020180141A (ja) 2020-11-05
CA2896568A1 (en) 2014-05-30
IL238979B (en) 2020-08-31
HK1215687A1 (zh) 2016-09-09
CN104981265A (zh) 2015-10-14
IL273912B2 (en) 2024-11-01
US20140148636A1 (en) 2014-05-29
EP3915551A1 (en) 2021-12-01
JP2016501865A (ja) 2016-01-21
US9649501B2 (en) 2017-05-16
ES2882619T3 (es) 2021-12-02
KR20220132667A (ko) 2022-09-30
US20150165224A1 (en) 2015-06-18
US20210101015A1 (en) 2021-04-08
IL273912A (en) 2020-05-31
US20180001104A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
ES2532140T3 (es) Aparato para la prescripción y administración controlada de tratamientos de estimulación transcraneal con corriente continua en humanos
EA201391328A1 (ru) Многофункциональный катетер
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CL2015002807A1 (es) Terapia de combinación
MX377877B (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MX2015011430A (es) Antagonismo de la miostatina en seres humanos.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CO2019005714A2 (es) Estimulación nerviosa eléctrica transcutánea usando una nueva forma de onda bifásica desequilibrada y nueva disposición de electrodos.
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
NZ630367A (en) Methods of treatment of pediatric solid tumor
GB2514504A (en) Apparatus and method for irradiating biological tissue
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
AR108519A1 (es) Composición farmacéutica que incluye un portador neutro tratado con energía y métodos de tratamiento relacionados
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX393475B (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2016003418A (es) Aparato de estimulacion electrica venosa y metodos.
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
GB2571919B (en) Improvements in and relating to electrodes for medical stimulating devices
HK1215687A1 (zh) 丘腦皮層節律異常的治療
MX2018000287A (es) Dispositivo de electroestimulacion.
EA201500137A1 (ru) Способ лечения аддикции